PPIG and metabolic dysfunction-associated steatohepatitis: Compound 11 emerged overall as a potent Cyp Binhibitor with 10-fold selectivity over Cyp A, encouraging drug safetyprofile and in vitro DMPK properties, as well asefficacy in reducing hepatic steatosis; a key component of MASH disease.Thus, this compound series has the potential to be useful to investigatethe therapeutic benefits of selective Cyp B inhibition in the contextof MASH and related liver diseases.